News

/News

X4 joins hands with Yale on rare disease program

Yale University has teamed up with cancer biotech X4 Pharmaceuticals to work on its therapy for WHIM syndrome, a rare genetic disorder that plays havoc with the immune system but has no approved treatment. The biotech—which specializes in drugs targeting the CXCR4 receptor—says it will help Yale investigate the molecular mechanisms behind WHIM syndrome, specifically the role that CXCR4 mutations may play in the disease. CXCR4 is the receptor for the chemokine CXCL12, and research has suggested that the interplay of the receptor and its ligand can downplay immune responses. more

By |August 20th, 2017|News|0 Comments

Alexion and Sema4 form strategic partnership

Alexion Pharmaceuticals and Sema4 today announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery. This new partnership will combine Alexion’s rare disease SmartPanel analytics with Sema4’s proven success in next-generation sequencing and genomic interpretation to further enable novel diagnostic and therapeutic insights into rare diseases. ​ more

By |August 20th, 2017|News|0 Comments

TIP companies help UConn students ‘start up’

Students who participated in the UConn-TIP Summer Fellowship discussed their experiences learning about startups and entrepreneurship at the finale of the 10-week immersion program. Local entrepreneurs, faculty, university staff, an official from state government, family, and friends of the participants gathered at the Cell and Genome Sciences Building in Farmington to hear what the students—and their mentors—learned over the course of the 10-week program. more

By |August 20th, 2017|News|0 Comments

Investor support spurs biotech progress in Stamford

Loxo Oncology and fellow Stamford biotech firm Cara Therapeutics have benefited from increasing investor confidence in their work. This year, the two enterprises have cumulatively attracted hundreds of millions of dollars to support their operations. Their records show biopharmaceutical businesses’ enduring ability to tap into large amounts of capital — if they have the scientific results to prove their progress.​ more

By |August 20th, 2017|News|0 Comments

Melinta merges with Cempra, adding anti-infectives

Melinta Therapeutics has struck a deal to merge with Cempra. The agreement brings together two of the biotechs developing anti-infective drugs. ​ New Haven-based Melinta will emerge from the merger as the dominant partner. Its name will stay above the door and its shareholders will control 52% of the combined company.​ more

By |August 20th, 2017|News|0 Comments

Avara acquires sterile facility from Pfizer

Avara Pharmaceutical Services has signed an agreement with Pfizer Inc. to acquire the Liscate, Italy sterile manufacturing facility. "This acquisition is an important component of our strategic plan and expands our services by adding sterile processing capability, which is in very high demand," stated Timothy C. Tyson, Chairman and CEO. more

By |August 20th, 2017|News|0 Comments

CURE welcomes new member The Luxi Group

The Luxi Group helps clients uncover new ways to relieve stress, navigate obstacles, and develop strategies to reach goals quickly and increase profits.The firm brings strategy, development and high-powered training to help clients build the right teams, both internally and with strategic partnerships, develop realistic plans that prioritize key initiatives, and integrate quality and regulatory compliance into effective business solutions.​ more

By |August 9th, 2017|News|0 Comments

Aetna, CDC to tackle antibiotic overuse

While Aetna and the Centers for Disease Control and Prevention play two very different roles in the healthcare world, they have recently begun working toward one common goal: reducing the frequency of unnecessary antibiotic prescriptions. Aetna got the partnership started by reaching out to the CDC to explore ways to better educate its network of providers about antibiotic stewardship, said Daniel Knecht, M.D., the company’s head of clinical strategy. more

By |August 9th, 2017|News|0 Comments

Roberts appointed to CT Health Data Collaborative

William J. Roberts, a partner in Shipman & Goodwin LLP’s Health Law Practice Group and Chair of the firm’s Privacy and Data Protection team, has been appointed to serve on the Connecticut Health Data Collaborative (CHDC) working group. The Connecticut Data Collaborative is a public-private partnership that advocates for the public availability of open and accessible data to drive planning, policy, budgeting and decision making in Connecticut at the state, regional and local levels. It is a user-driven organization, serving nonprofits, advocates, policymakers, community groups, and funders in using data to drive policy and improve programs and services. more

By |August 9th, 2017|News|0 Comments

Young entrepreneurs team up at Quinnipiac

The Center for Innovation and Entrepreneurship, jointly with the Central European Institute recently organized the first annual Quinnipiac University Entrepreneurship and Leadership Academy – International Session, Summer ‘17 in Connecticut. The program aimed to teach the principal, often neglected equation of entrepreneurship: Innovation = Idea x Commercialization. The seven-day entrepreneurial experience included an intensive five-day course of top-tier business lectures, workshops, and field trips, mentored by experts and business leaders from the New England Region. His Excellency Consul General of Hungary Ferenc Kumin gave special remarks, and emphasized the importance of European-American joint ventures and similar initiatives to build bridges [...]

By |August 9th, 2017|News|0 Comments